GSK (LON:GSK) PT Set at GBX 1,350 by JPMorgan Chase & Co.

GSK (LON:GSKGet Rating) received a GBX 1,350 ($16.45) target price from investment analysts at JPMorgan Chase & Co. in a research report issued on Wednesday, Borsen Zeitung reports. JPMorgan Chase & Co.‘s price target suggests a potential downside of 5.66% from the company’s previous close.

Several other research analysts have also weighed in on the stock. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 1,500 ($18.27) price objective on shares of GSK in a research note on Monday, December 5th. Shore Capital reiterated a “buy” rating on shares of GSK in a research note on Thursday, December 15th. Berenberg Bank set a GBX 1,580 ($19.25) price target on shares of GSK in a research note on Thursday, November 24th. Credit Suisse Group set a GBX 1,510 ($18.40) price target on shares of GSK in a research note on Friday, January 6th. Finally, Jefferies Financial Group set a GBX 1,575 ($19.19) price target on shares of GSK in a research note on Thursday, January 5th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of GBX 1,518.89 ($18.50).

GSK Stock Up 1.5 %

GSK stock opened at GBX 1,431 ($17.43) on Wednesday. The firm has a market capitalization of £58.59 billion and a PE ratio of 1,312.84. The company’s 50-day moving average is GBX 1,419.27 and its 200-day moving average is GBX 1,466.89. GSK has a fifty-two week low of GBX 1,280.92 ($15.61) and a fifty-two week high of GBX 2,280.50 ($27.78). The company has a debt-to-equity ratio of 253.74, a current ratio of 0.97 and a quick ratio of 0.73.

Insider Transactions at GSK

In other news, insider Jonathan Symonds purchased 2,100 shares of the business’s stock in a transaction dated Tuesday, December 20th. The stock was bought at an average price of GBX 1,417 ($17.26) per share, with a total value of £29,757 ($36,253.65). In other news, insider Jonathan Symonds purchased 2,100 shares of the business’s stock in a transaction dated Tuesday, December 20th. The stock was bought at an average price of GBX 1,417 ($17.26) per share, with a total value of £29,757 ($36,253.65). Also, insider Urs Rohner purchased 798 shares of the business’s stock in a transaction dated Thursday, December 22nd. The shares were purchased at an average cost of GBX 1,453 ($17.70) per share, with a total value of £11,594.94 ($14,126.39). In the last 90 days, insiders bought 2,915 shares of company stock valued at $4,159,115.

About GSK

(Get Rating)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Stories

Analyst Recommendations for GSK (LON:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.